BioSpace News Archive

Nabsys, the pioneer in high-definition genome mapping, announced that it has closed on a $21 million equity round led by Hitachi High-Technologies Corporation.

Management will host its third quarter 2019 conference call on Monday, November 11, 2019 to provide a corporate update and review the Company’s poster presentations from SITC

Kindred Biosciences, Inc. announced the closing of a $50 million senior secured debt facility with investment affiliates managed by Solar Capital Partners, LLC.

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will be providing an overview of the Company’s clinical pipeline following recent updates on the AVP-786 partnered program in a presentation at the Cantor Healthcare Conference on Thursday, October 3, 2019 at 5:20 p.m. ET in New York, NY.

Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced data presentations regarding two of its wholly owned prophylactic mRNA vaccines at IDWeek in Washington, D.C.

ArQule, Inc. (Nasdaq: ARQL), today announced that the first patient was dosed in the registrational MOSAIC (Miransertib in Overgrowth Syndromes in Adults and Children) trial of its oral, selective pan-AKT inhibitor, miransertib, for the treatment of Proteus syndrome (PS) and PIK3CA-related Overgrowth Spectrum disorders (PROS).

Torque Therapeutics, a clinical stage, product-platform company developing proprietary, first-in-class Deep Primed™ adoptive cell transfer therapeutics with uniquely broad potential to treat patients with a wide range of hematologic and solid malignancies, announced the appointment of John Cox as Chief Executive Officer.

The CARESTAR Foundation has awarded a grant for key training and equipment to Tahoe Forest Hospital, a rural critical access hospital in Truckee, CA.

Software integration will help providers augment and extend EHR functionality, driving greater clinician satisfaction

DURECT Corporation announced that the U.S. Food and Drug Administration has notified the Company that its Class 2 NDA resubmission for POSIMIR® will be discussed at a meeting of the Anesthetic and Analgesic Drug Products Advisory Committee.